{"id":"https://openalex.org/W2084136102","doi":"https://doi.org/10.1158/1535-7163.targ-13-b123","title":"Abstract B123: Preclinical evaluation of FS102: A HER2-specific Fcab with a novel mechanism of action.","display_name":"Abstract B123: Preclinical evaluation of FS102: A HER2-specific Fcab with a novel mechanism of action.","publication_year":2013,"publication_date":"2013-11-01","ids":{"openalex":"https://openalex.org/W2084136102","doi":"https://doi.org/10.1158/1535-7163.targ-13-b123","mag":"2084136102"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-13-b123","doi":"https://doi.org/10.1158/1535-7163.targ-13-b123","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-13-b123","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054010071","display_name":"Sarah Batey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210153030","display_name":"F-star (United Kingdom)","ror":"https://ror.org/04amrty77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210153030"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sarah Batey","raw_affiliation_strings":["F-star, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F-star, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I4210153030"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086961491","display_name":"Kin-Mei Leung","orcid":"https://orcid.org/0000-0002-2019-3001","observed_orcids":["https://orcid.org/0000-0002-2019-3001"]},"institutions":[{"id":"https://openalex.org/I4210153030","display_name":"F-star (United Kingdom)","ror":"https://ror.org/04amrty77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210153030"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Kinmei Leung","raw_affiliation_strings":["F-star, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F-star, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I4210153030"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069403904","display_name":"Robert J. Rowlands","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210153030","display_name":"F-star (United Kingdom)","ror":"https://ror.org/04amrty77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210153030"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Robert Rowlands","raw_affiliation_strings":["F-star, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F-star, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I4210153030"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087569309","display_name":"Samine J. Isaac","orcid":"https://orcid.org/0000-0003-2926-9727","observed_orcids":["https://orcid.org/0000-0003-2926-9727"]},"institutions":[{"id":"https://openalex.org/I4210153030","display_name":"F-star (United Kingdom)","ror":"https://ror.org/04amrty77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210153030"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Samine Isaac","raw_affiliation_strings":["F-star, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F-star, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I4210153030"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101440519","display_name":"Joana Carvalho","orcid":"https://orcid.org/0000-0002-9056-5472","observed_orcids":["https://orcid.org/0000-0002-9056-5472"]},"institutions":[{"id":"https://openalex.org/I4210153030","display_name":"F-star (United Kingdom)","ror":"https://ror.org/04amrty77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210153030"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Joana Carvalho","raw_affiliation_strings":["F-star, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F-star, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I4210153030"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Sarah Weller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210153030","display_name":"F-star (United Kingdom)","ror":"https://ror.org/04amrty77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210153030"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sarah Weller","raw_affiliation_strings":["F-star, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F-star, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I4210153030"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088008465","display_name":"Mateusz M. Wydro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210153030","display_name":"F-star (United Kingdom)","ror":"https://ror.org/04amrty77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210153030"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Mateusz Wydro","raw_affiliation_strings":["F-star, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F-star, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I4210153030"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005695749","display_name":"Miguel A. Gaspar","orcid":"https://orcid.org/0009-0001-2711-9875","observed_orcids":["https://orcid.org/0009-0001-2711-9875"]},"institutions":[{"id":"https://openalex.org/I4210153030","display_name":"F-star (United Kingdom)","ror":"https://ror.org/04amrty77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210153030"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Miguel Gaspar","raw_affiliation_strings":["F-star, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F-star, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I4210153030"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048510072","display_name":"Melanie Medcalf","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210153030","display_name":"F-star (United Kingdom)","ror":"https://ror.org/04amrty77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210153030"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Melanie Medcalf","raw_affiliation_strings":["F-star, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F-star, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I4210153030"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082962651","display_name":"Robert Pegram","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210153030","display_name":"F-star (United Kingdom)","ror":"https://ror.org/04amrty77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210153030"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Robert Pegram","raw_affiliation_strings":["F-star, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F-star, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I4210153030"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085830500","display_name":"Vicky Drewett","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210153030","display_name":"F-star (United Kingdom)","ror":"https://ror.org/04amrty77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210153030"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Vicky Drewett","raw_affiliation_strings":["F-star, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F-star, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I4210153030"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051439913","display_name":"Mihriban Tuna","orcid":"https://orcid.org/0000-0001-9059-9990","observed_orcids":["https://orcid.org/0000-0001-9059-9990"]},"institutions":[{"id":"https://openalex.org/I4210153030","display_name":"F-star (United Kingdom)","ror":"https://ror.org/04amrty77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210153030"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Mihriban Tuna","raw_affiliation_strings":["F-star, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F-star, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I4210153030"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028710666","display_name":"John S\u00f8rensen Haurum","orcid":"https://orcid.org/0000-0003-1564-9171","observed_orcids":["https://orcid.org/0000-0003-1564-9171"]},"institutions":[{"id":"https://openalex.org/I4210153030","display_name":"F-star (United Kingdom)","ror":"https://ror.org/04amrty77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210153030"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"John Haurum","raw_affiliation_strings":["F-star, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F-star, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I4210153030"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112860599","display_name":"Haijun Sun","orcid":"https://orcid.org/0009-0004-5967-5595","observed_orcids":["https://orcid.org/0009-0004-5967-5595"]},"institutions":[{"id":"https://openalex.org/I4210153030","display_name":"F-star (United Kingdom)","ror":"https://ror.org/04amrty77","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210153030"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Haijun H. Sun","raw_affiliation_strings":["F-star, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F-star, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I4210153030"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210153030"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"12","issue":"11_Supplement","first_page":"B123","last_page":"B123"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.009100000374019146,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.8309999704360962},{"id":"https://openalex.org/keywords/her2-positive-gastric-cancer","display_name":"HER2-positive gastric cancer","score":0.8569999933242798},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.8980000019073486},{"id":"https://openalex.org/keywords/pertuzumab","display_name":"pertuzumab","score":0.9729999899864197},{"id":"https://openalex.org/keywords/her2-downregulation","display_name":"HER2 downregulation","score":0.7379999756813049},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.9229999780654907},{"id":"https://openalex.org/keywords/cell-cycle-arrest","display_name":"cell cycle arrest","score":0.6819999814033508},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.8519999980926514},{"id":"https://openalex.org/keywords/her2-targeted-therapy","display_name":"HER2-targeted therapy","score":0.5130000114440918},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.5080000162124634}],"concepts":[{"id":"https://openalex.org/C191560914","wikidata":"https://www.wikidata.org/wiki/Q7390592","display_name":"SKBR3","level":5,"score":0.9203758835792542},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.9183753728866577},{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.8861367702484131},{"id":"https://openalex.org/C195616568","wikidata":"https://www.wikidata.org/wiki/Q128711","display_name":"Epitope","level":3,"score":0.7814635634422302},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.556475818157196},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5492862462997437},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.5101035237312317},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.47583723068237305},{"id":"https://openalex.org/C2779707156","wikidata":"https://www.wikidata.org/wiki/Q5611758","display_name":"Growth inhibition","level":3,"score":0.4444687068462372},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4348139762878418},{"id":"https://openalex.org/C2776120743","wikidata":"https://www.wikidata.org/wiki/Q3271540","display_name":"Mechanism of action","level":3,"score":0.43348583579063416},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.429095983505249},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39473241567611694},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3912399113178253},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.3484684228897095},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3186050057411194},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.27212733030319214},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.2630152106285095},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2306353747844696},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.17785382270812988},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1563814878463745},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C2994423619","wikidata":"https://www.wikidata.org/wiki/Q9103","display_name":"Human breast","level":4,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-13-b123","doi":"https://doi.org/10.1158/1535-7163.targ-13-b123","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-13-b123","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1510837654","https://openalex.org/W2090810974","https://openalex.org/W3008108916","https://openalex.org/W3209501532","https://openalex.org/W197699128","https://openalex.org/W2264655007","https://openalex.org/W2123646476","https://openalex.org/W2517105328","https://openalex.org/W2016369535","https://openalex.org/W2129750399"],"abstract_inverted_index":{"Abstract":[0],"HER2":[1,69,124,172,203,283,385],"is":[2,8,325,397],"a":[3,30,57,92,115,264,294,388,470],"validated":[4],"oncogenic":[5],"target":[6],"which":[7,67,290],"overexpressed":[9],"in":[10,46,99,135,138,143,161,198,282,304,316,333,387],"many":[11],"cancers.":[12],"Although":[13],"the":[14,20,47,84,105,122,153,167,193,222,334,348,369,378,394,418,479],"approved":[15],"HER2-specific":[16,58,467],"biologics":[17,404],"have":[18,108,377],"improved":[19],"standard":[21],"of":[22,24,50,86,95,141,169,231,266,319,337,342,368,464,473,478],"care":[23],"HER2-positive":[25,154],"breast":[26,155,308],"and":[27,75,137,179,183,201,207,263,307,362,392,409,485],"gastric":[28],"cancers,":[29],"significant":[31],"unmet":[32],"medical":[33],"need":[34],"exists":[35],"due":[36],"to":[37,107,111,145,275,352,365,380,383,401,415],"intrinsic":[38],"or":[39,88,148],"acquired":[40],"resistance.":[41],"By":[42],"randomizing":[43],"two":[44,223],"loops":[45],"CH3":[48],"domain":[49],"an":[51,77,160,269,398],"IgG1":[52],"Fc":[53],"fragment,":[54],"we":[55,133,165],"generated":[56],"Fcab\u2122":[59],"(Fc":[60],"fragment":[61],"with":[62,70,83,121,235,405,469],"antigen":[63,407],"binding),":[64],"called":[65],"FS102,":[66],"binds":[68],"high":[71],"affinity":[72],"(2":[73],"nM),":[74],"recognizes":[76],"epitope":[78,125],"that":[79,374,393],"does":[80],"not":[81,271],"overlap":[82],"epitopes":[85],"trastuzumab":[87,146,184,238,330],"pertuzumab.":[89],"FS102":[90,142,170,182,208,245,254,277,324,357,375],"has":[91,103,301],"favorable":[93],"t1/2":[94],"\u223c":[96],"60":[97],"hours":[98],"mice.":[100],"Biophysical":[101],"characterization":[102,140],"shown":[104],"Fcab":[106,395,468],"suitable":[109],"properties":[110],"be":[112],"developed":[113],"as":[114,159,258],"therapeutic.":[116],"To":[117],"assess":[118],"if":[119],"interactions":[120],"unique":[123,406],"could":[126],"translate":[127],"into":[128],"clinically":[129,295],"relevant":[130,296],"pharmacological":[131],"activities,":[132],"conducted":[134],"vitro":[136,162],"vivo":[139],"comparison":[144],"monotherapy":[147],"trastuzumab-pertuzumab":[149,353],"combination":[150,354],"therapy.":[151],"Using":[152],"cell":[156,176,199,212,241,250],"line":[157],"SKBr3":[158,189,211],"model":[163,345],"system,":[164],"determined":[166],"effect":[168,248,270],"on":[171,249],"downregulation,":[173],"cellular":[174],"proliferation,":[175],"cycle":[177,242,251],"progression,":[178],"apoptosis.":[180],"Both":[181],"were":[185,350],"internalized":[186],"efficiently":[187],"by":[188,214,260],"cells,":[190],"but":[191],"only":[192],"former":[194],"induced":[195,239,256],"profound":[196],"reduction":[197],"surface":[200],"total":[202],"protein":[204],"levels.":[205],"Trastuzumab":[206],"both":[209],"reduced":[210],"proliferation":[213],"approximately":[215],"50%":[216],"upon":[217,273],"5":[218],"days":[219],"treatment.":[220],"However":[221],"agents":[224],"achieved":[225],"this":[226],"inhibition":[227,300],"via":[228],"distinct":[229],"mechanisms":[230],"action":[232],"(MOA).":[233],"Consistent":[234],"published":[236],"data,":[237],"G1":[240],"arrest,":[243],"while":[244],"showed":[246],"no":[247],"progression.":[252],"Instead,":[253],"significantly":[255,326],"apoptosis":[257],"measured":[259],"caspase":[261],"activity":[262],"loss":[265],"membrane":[267],"integrity,":[268],"observed":[272,303],"exposure":[274],"trastuzumab.":[276],"displays":[278],"potent":[279],"anti-tumor":[280],"effects":[281],"overexpressing":[284],"patient-derived":[285],"xenograft":[286],"(PDX)":[287],"murine":[288],"models,":[289],"are":[291,413],"positive":[292],"for":[293],"biomarker.":[297],"Significant":[298],"tumor":[299,314,360],"been":[302],"gastric,":[305],"colorectal":[306],"PDX":[309,338,344],"models.":[310],"This":[311],"includes":[312],"complete":[313,366],"regression":[315,367],"3":[317],"out":[318],"8":[320],"models":[321],"evaluated.":[322],"Moreover,":[323],"more":[327],"effective":[328],"than":[329],"when":[331],"tested":[332],"biomarker-positive":[335],"subset":[336],"tumors.":[339],"In":[340],"one":[341],"these":[343],"systems,":[346],"where":[347],"tumors":[349],"refractory":[351],"treatment,":[355],"subsequent":[356],"treatment":[358],"reversed":[359],"growth":[361],"ultimately":[363],"led":[364],"tumor.":[370],"The":[371],"results":[372],"indicate":[373],"may":[376],"potential":[379],"overcome":[381],"resistance":[382],"conventional":[384],"therapy":[386],"biomarker-defined":[389],"patient":[390],"subpopulation,":[391],"technology":[396],"attractive":[399],"platform":[400],"generate":[402],"novel":[403,471],"recognition":[408],"MOA.":[410],"Additional":[411],"studies":[412],"underway":[414],"further":[416],"elucidate":[417],"FS102-induced":[419],"ErbB":[420],"receptor":[421],"degradation":[422],"pathway.":[423],"Citation":[424,431],"Information:":[425],"Mol":[426,496],"Cancer":[427,486,497],"Ther":[428,498],"2013;12(11":[429,499],"Suppl):B123.":[430],"Format:":[432],"Sarah":[433,443],"Batey,":[434],"Kinmei":[435],"Leung,":[436],"Robert":[437,451],"Rowlands,":[438],"Samine":[439],"Isaac,":[440],"Joana":[441],"Carvalho,":[442],"Weller,":[444],"Mateusz":[445],"Wydro,":[446],"Miguel":[447],"Gaspar,":[448],"Melanie":[449],"Medcalf,":[450],"Pegram,":[452],"Vicky":[453],"Drewett,":[454],"Mihriban":[455],"Tuna,":[456],"John":[457],"Haurum,":[458],"Haijun":[459],"H.":[460],"Sun.":[461],"Preclinical":[462],"evaluation":[463],"FS102:":[465],"A":[466],"mechanism":[472],"action.":[474],"[abstract].":[475],"In:":[476],"Proceedings":[477],"AACR-NCI-EORTC":[480],"International":[481],"Conference:":[482],"Molecular":[483],"Targets":[484],"Therapeutics;":[487],"2013":[488],"Oct":[489],"19-23;":[490],"Boston,":[491],"MA.":[492],"Philadelphia":[493],"(PA):":[494],"AACR;":[495],"Suppl):Abstract":[500],"nr":[501],"B123.":[502]},"counts_by_year":[{"year":2015,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}